• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

iScience . Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses

tetano

Editor, Senior Moderator
iScience


. 2023 Apr 21;26(4):106540.
doi: 10.1016/j.isci.2023.106540. Epub 2023 Mar 31.
Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses


Laura Radić[SUP] 1 2 [/SUP], Kwinten Sliepen[SUP] 1 2 [/SUP], Victor Yin[SUP] 3 4 [/SUP], Mitch Brinkkemper[SUP] 1 2 [/SUP], Joan Capella-Pujol[SUP] 1 2 [/SUP], Angela I Schriek[SUP] 1 2 [/SUP], Jonathan L Torres[SUP] 5 [/SUP], Sandhya Bangaru[SUP] 5 [/SUP], Judith A Burger[SUP] 1 2 [/SUP], Meliawati Poniman[SUP] 1 2 [/SUP], Ilja Bontjer[SUP] 1 2 [/SUP], Joey H Bouhuijs[SUP] 1 2 [/SUP], David Gideonse[SUP] 6 [/SUP], Dirk Eggink[SUP] 6 [/SUP], Andrew B Ward[SUP] 5 [/SUP], Albert J R Heck[SUP] 3 4 [/SUP], Marit J Van Gils[SUP] 1 2 [/SUP], Rogier W Sanders[SUP] 1 2 [/SUP], Janke Schinkel[SUP] 1 2 [/SUP]



Affiliations

Abstract

SARS-CoV-2 variants evade current monoclonal antibody therapies. Bispecific antibodies (bsAbs) combine the specificities of two distinct antibodies taking advantage of the avidity and synergy provided by targeting different epitopes. Here we used controlled Fab-arm exchange to produce bsAbs that neutralize SARS-CoV and SARS-CoV-2 variants, including Omicron and its subvariants, by combining potent SARS-CoV-2-specific neutralizing antibodies with broader antibodies that also neutralize SARS-CoV. We demonstrated that the parental antibodies rely on avidity for neutralization using bsAbs containing one irrelevant Fab arm. Using mass photometry to measure the formation of antibody:spike complexes, we determined that bsAbs increase binding stoichiometry compared to corresponding cocktails, without a loss of binding affinity. The heterogeneous binding pattern of bsAbs to spike, observed by negative-stain electron microscopy and mass photometry provided evidence for both intra- and inter-spike crosslinking. This study highlights the utility of cross-neutralizing antibodies for designing bivalent agents to combat circulating and future SARS-like coronaviruses.

Keywords: Immunology; Structural biology; Virology.
 
Back
Top Bottom